# BlueDot

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/bluedot

- Industry: Healthcare IT
- Headquarters: Toronto, Canada
- Website: http://www.bluedot.global
- Total disclosed funding: $7M
- Latest round: Series A (Aug 7, 2019)
- Investors on record: 3

## About

BlueDot Inc. specializes in infectious disease intelligence, providing essential solutions for public health preparedness through global surveillance and predictive analytics.Founded in 2013 and headquartered in Toronto, Canada, BlueDot Inc. focuses on infectious disease monitoring and response. The company was co-founded by Fatemeh Niari and Kamran Khan, who also serves as CEO. BlueDot has secured funding through three deals, with its most recent funding round, Series A, raising USD 7.000 mn from investors BDC Capital, Horizons Ventures, and The Co-operators Group Limited on August 7, 2019.BlueDot provides advanced infectious disease intelligence solutions designed to enhance public health preparedness and response capabilities. Central to their offerings is an always-on global surveillance system that monitors over 190 infectious diseases and syndromes, enabling clients to be the first to know about high-consequence threats. The company utilizes a risk analysis toolkit and predictive intelligence to analyze global data on disease spread, population vulnerability, and outbreak suitability, allowing organizations to make informed decisions regarding their health security. BlueDot's clientele includes governments, public health organizations, and enterprises in various sectors, such as pharmaceuticals and life sciences, aiming to safeguard populations against outbreaks that could disrupt health, economic stability, and social structures. Their products are utilized worldwide, with notable implementations in markets across North America, Europe, and parts of Asia.BlueDot generates revenue through subscription-based models and partnerships with various clients, including governments and global enterprises. Clients typically engage with BlueDot through structured agreements that provide access to its suite of intelligence solutions, including outbreak alerts, risk assessments, and forecasting models. These services are tailored to meet the specific needs of different sectors, including public health and pharmaceuticals, ensuring that infectious disease countermeasures are effectively deployed. The transaction structure is designed to facilitate ongoing engagement with clients, providing continuous monitoring and updates on emerging threats. While specific pricing plans for individual services are not disclosed, the financial framework reflects a commitment to delivering value through timely intelligence and expert analysis.BlueDot plans to leverage its recent Series A funding of USD 7.000 mn, raised in August 2019, to enhance its product offerings and market reach. The company aims to expand its global surveillance capabilities and launch new predictive tools tailored for specific industries by the end of 2023. Additionally, BlueDot is targeting growth in new markets, particularly in Europe and Asia, where it sees significant potential for its intelligence solutions.

## Funding rounds

- Series A, Aug 7, 2019, $7M — BDC Capital, Horizons Ventures, The Co-operators Group Limited

## Investors

- BDC Capital (https://capitalatlas.ai/funds/bdc-capital) — Series A
- Horizons Ventures — Series A
- The Co-operators Group Limited — Series A